Zynlonta (Loncastuximab Tesirine-Lpyl) Patent Expiration, LOE Window & CMS Spending

Zynlonta (Loncastuximab Tesirine-Lpyl) by ADC Therapeutics SA: Biologic BLA (Purple Book Regime), 0 AB generics, $2.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorADC Therapeutics SA
FDA Application & PathwayB761196 (BLA)
Exclusivity / Cliff HorizonBiologic BLA (Purple Book Regime)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$2.7M
2024 Medicare Part D Spend$288K
2024 Medicaid Spend$2.4M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 17.4% 2-yr change)